SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Addressing the Full Spectrum of Cardiovascular Disease Complexity

The SYNERGY™ Bioabsorbable Polymer (BP) Stent is being studied in 20 investigator-sponsored research trials including more than 30,000 patients, allowing physicians worldwide to provide data on patients receiving the SYNERGY BP Stent.

We are investing in the science to address significant unmet clinical needs. We are the only company running an IDE trial to evaluate a 3-month DAPT regimen in BP-DES patients with a high bleeding risk.

SYNERGY BP Stent Clinical Program and Investigator-Sponsored Research*

The safety and efficacy of the SYNERGY Stent has not been established in CTOs

* Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific’s involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products.

 

Boston Scientific Clinical Trial Program

The EVOLVE II Clinical Trial studied 1,684 patients, the broadest and most complex patient population ever studied in a U.S. pivotal stent trial. The results showed exceptionally low stent thrombosis favoring BP-DES versus PP-DES at 4-Years.1

Numerically Lower ARC Definite/Probable Stent Thrombosis
Landmark Analysis After 24-Hours

EVOLVE II 4-year ST Landmark

† CEC confirmed MI/TLR/ST Day 901 in the SYNERGY arm 37 y/o male patient had 1,1,0 distal RCA/PDA bifurcation lesion, and a second lesion in the mid-LAD treated during the index procedure (patient was discharged on DAPT [clopidogrel]. On day 840, patient had TLR of 75% in-stent restenosis of the distal RCA/PDA lesion performed with drug coated balloon (patient was discharged on DAPT [prasugrel]). On day 901, patient developed severe chest pain, ST elevation and marked elevation of cardiac enzymes. Found to have ST of RCA/PDA lesion, which was successfully treated with another stent. ITT; Patients who did not receive a study stent were censored at 1 year; KM Event Rate; log-rank P values.
 
Watch Prof. Ian Meredith, Global Chief Medical Officer for Boston Scientific, and other global KOLs discuss the 4-year results from the EVOLVE II Trial and recent evidence on short DAPT from the SENIOR Trial.
 
The EVOLVE II Diabetic Substudy led to the indication of the SYNERGY BP Stent for use in patients with Diabetes Mellitus.

Primary Endpoint of 12-Month Target Lesion Failure was Met2

P-value from the one-sided Clopper-Pearson test is <0.025, the 12-month TLF rate from SYNERGY is concluded to be less than the performance goal (14.5%)

One-sided 97.5% Clopper Pearon Upper Confidence Bound (UCB) Target lesion failure (TLF) defined as: Cardiac death, or MI related to the target vessel (based on CK-MB >3x URL), or Ischemia-driven target lesion revascularization

 

The EVOLVE first human use trial demonstrated outstanding long-term safety and performance with the SYNERGY BP Stent.

EVOLVE Trial 5-Year Results3

Learn more about the clinical data in real-world populations

Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top